ARMP · Armata Pharmaceuticals, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash and cash equivalents of $24.0 million as of June 30, 2026 will not be sufficient to enable us to complete all necessary development of any potential product candidates and fund our operations for the next 12 months from the date the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $25.59M | $23.72M | $34.43M | $33.77M | $35.02M | $20.02M | $14.44M | $9.82M | $8.37M | $2.88M | $5.68M | $3.99M | $5.81M | $6.47M | |
| $15.24M | $12.41M | $13.18M | $11.65M | $7.44M | $8.28M | $7.97M | $9.27M | $2.52M | $7.59M | $8.41M | $6.71M | $6.85M | $6M | |
| $31K | — | — | — | — | — | — | — | $31K | $31K | $31K | $31K | $31K | $31K | |
| $1.49M | — | $1.33M | $972K | $892K | — | — | — | — | — | — | — | — | — | |
| $46.24M | $41.54M | $47.61M | $45.42M | $42.45M | $28.3M | $22.41M | $19.75M | $17.66M | $16.27M | $23.64M | $10.7M | $14.52M | $12.47M | |
| -$40.7M | -$36.63M | -$42.44M | -$40.89M | -$36.95M | -$23.82M | -$21.59M | -$19.75M | -$17.66M | -$16.16M | -$23.38M | -$10.23M | -$14.11M | -$12.38M | |
| — | — | — | — | $0 | $64K | $628K | $931K | $1.01M | — | $6000 | — | $0 | $233K | |
| $388K | — | — | $179K | $29K | $5000 | $28K | $96K | $245K | — | — | — | — | — | |
| -$151.48M | -$137.17M | $23.52M | -$28.16M | $29K | $667K | -$594K | $273K | $956K | $2.02M | $3.98M | $9.64M | $37.22M | -$52.2M | |
| — | -$173.8M | -$18.92M | -$69.05M | -$36.92K | -$23.16M | -$22.18M | -$19.48M | -$16.7M | -$14.14M | -$19.39M | -$589K | $23.11M | — | |
| — | — | — | — | — | — | — | — | -$328K | -$1.3M | -$556K | -$73K | — | — | |
| -$192.18M | -$173.8M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.7M | -$12.84M | -$18.84M | -$516K | $23.11M | -$64.58M | |
| — | -$173.8M | -$18.92M | -$69.05M | — | — | — | -$19.48M | -$16.7M | -$12.84M | -$24.28M | -$10.79M | $15.76M | -$65.2M | |
| $23.35M | — | — | — | — | — | — | — | — | — | — | — | — | -$57.61M | |
| USD/shares | -$5.31 | -$4.80 | -$0.52 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.49 | -$3.59 | -$2.01 | -$24.67 | -$1.99 | $4.21 | -$0.64 |
| USD/shares | -$7.58 | -$4.80 | -$0.89 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.55 | -$3.59 | -$2.18 | -$24.67 | -$1.99 | -$2.33 | -$0.64 |
| shares | — | 36.24M | 36.16M | 36.08M | 34.29M | 24.1M | 16.42M | 7.83M | 4.65M | 6.39M | 983.85K | 5.41M | 3.75M | 101.2M |
| shares | — | 36.24M | 59.06M | 36.08M | 34.29M | 24.1M | 16.42M | 8.01M | 4.65M | 6.57M | 983.85K | 5.41M | 5.89M | 101.2M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 306 similar-size Biotechnology companies (of 532 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -$36,634,000 | -$42,436,000 | -$40,890,000 |